Immunomodulatory Compositions for Systemic Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of understanding of how probiotics in plant-based diets modulate the immune system, and effective options for managing aging-associated inflammation and related diseases are limited, with commercial probiotics offering only a small number of bacterial and fungal species.
Innovation Solution
Pharmaceutical compositions comprising specific microbial entities with defined 16S rDNA or 18S rDNA sequences, functional expression sequences, or metabolic signatures, delivered via pharmaceutically acceptable vehicles, to target and modulate the immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If commercial probiotics are used, then a small number of bacterial and fungal species are provided, but the ability to address systemic inflammation in the aging population is limited
Solution Approach 1:
The invention segments the probiotic formulation into multiple distinct microbial entities (bacterial and fungal species) with specific functional characteristics. Each microbe is selected and characterized for its ability to produce specific metabolites or modulate specific immune pathways, allowing the formulation to address multiple aspects of inflammation simultaneously while maintaining a manageable number of well-defined components.
Solution Approach 2:
The probiotic formulation achieves multi-functionality by selecting microbial entities that can simultaneously perform multiple functions: producing anti-inflammatory metabolites, modulating immune cell activity, and maintaining gut barrier integrity. This allows a single formulation to address systemic inflammation in aging populations through diverse mechanisms rather than requiring numerous specialized microbes.
2Reliability
If plant-based diets with diverse microbes are consumed, then benefits for weight management and healthy lifestyle are achieved, but the mechanistic association between microbes and these benefits is not clear
Solution Approach 1:
The invention extracts and isolates specific microbial entities from the complex plant-based diet microbiome, separating them from the dietary context. These isolated microbes are then characterized for their specific functional properties (metabolite production, immune modulation) to elucidate the mechanisms by which they confer health benefits, independent of the complex dietary matrix.
Solution Approach 2:
The invention identifies and characterizes specific microbial metabolites and molecules as intermediaries that mediate the effects of plant-based microbes on host health. These intermediaries (such as short-chain fatty acids, polyphenol metabolites, or other bioactive compounds) provide a tangible mechanism linking microbial consumption to observed health benefits like weight management and inflammation reduction.
3Object-generated harmful factors
If probiotic supplementation is used, then systemic inflammatory biomarkers are reduced, but the understanding of how probiotics modulate the immune system remains insufficient
Solution Approach 1:
The invention performs preliminary characterization and classification of probiotic microbial entities before use, determining their functional properties, metabolite profiles, and immune modulation capabilities in advance. This preliminary understanding guides the selection and combination of microbes in the formulation, allowing for optimized anti-inflammatory effects while providing a framework for understanding the mechanisms involved.
Data Source
AI summary
This disclosure provides for compositions (e.g., pharmaceutical compositions, dietary supplements, medical foods and food stuff), comprising combinations of live microbe populations for the treatment and/or prevention of immune system disorders and conditions related to inflammation, including both pathogen assisted conditions and conditions that are independent of pathogens. Included with the present disclosure are methods for use of the compositions, and methods for selecting microbial entities to formulate the compositions of the disclosure.